从基于博尔特佐米布的疗法向IRd的类型过渡是新诊断的多发性骨髓瘤的有效方法
Robert M Rifkin1, Caitlin L Costello2, Ruemu E Birhiray3
1Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA.
Future oncology (London, England)
|October 9, 2023
概括
在博特佐米布诱导后切换到ixazomib-lenalidomide-dexamethasone (IRd) 改善了多发性骨髓瘤治疗反应和持续时间,而不是继续治疗博特佐米布.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 多发性骨髓瘤 (MM) 治疗通常涉及复杂的治疗方案.
- 亲肠道博雷佐米布基诱导,然后口服治疗是一种常见的策略.
- 优化治疗过渡对于患者的治疗结果至关重要.
研究的目的:
- 为了比较一类内过渡到全口服艾克萨佐米布-莱纳利多米德-德甲 (IRd) 与继续基于博特佐米布 (V) 的治疗的有效性.
- 评估新诊断的,非移植符合条件的MM患者的治疗反应和持续时间.
主要方法:
- 对两个患者队列的回顾性分析:美国MM-6 (过渡到IRd,N=100) 和INSIGHT MM (持续V基治疗,N=111).
- 患者是新诊断的MM的非移植合格患者.
- 治疗权重的逆概率被用于分析.
主要成果:
- 总体响应率 (ORR) 与基于V的疗法 (57.5%) 相比,IRd (73.2%) 的整体响应率显著更高 (p < 0.0001).
- 在IRd (10.8个月) 与基于V的治疗 (5.3个月) 中,治疗的平均持续时间更长 (p < 0.0001).
- 由于不良事件而停止治疗的比例为IRd的18%和基于V的治疗的24%.
结论:
- 在基于V的诱导后过渡到全口服IRd显著改善了MM的ORR和治疗持续时间.
- 与持续的基于V的疗法相比,IRd提供了一个潜在的更有效和更持久的治疗选择.
- 进一步的研究可能会探索长期的结果和生活质量.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
178
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
178
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
544
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544
Inflammatory Bowel Disease IV: Pharmacological Management
137
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
137


